Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and increased the price target from $40 to $50.
February 28, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Tarsus Pharmaceuticals and raised the price target from $40 to $50.
The upgrade in the price target by a reputable analyst like Balaji Prasad from Barclays indicates a strong confidence in Tarsus Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100